Amniotic fluid topical formulation
AssigneeMAM Holdings of West Florida, L.L.C.
InventorCarl Randall Harrell
Life of this patent
Estimating the term…
Abstract
A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.
Claims14
A method of treating, alleviating, or preventing a disorder, a disease, or an injury associated with the eye comprising administering to the eye an effective amount of a sterile serially filtered de-cellularized human amniotic fluid (D-HAF) devoid of all amniotic stem cells, insoluble elements of micronized membrane, and chorion particles,
- thereby treating, alleviating, or preventing one or more symptoms associated with the disorder, disease, or injury associated with the eye;
- wherein the D-HAF is not heat-treated, chemical treated, or gamma-irradiated, and is sterilized only by filtration;
- wherein the D-HAF is administered with or without implementation of an implant;
- and
- wherein the D-HAF is administered in a form selected from the group consisting of a solution, a suspension, an ointment, a gel, a spray, and a droplet.
Dependencies are inferred from the claim text.